What is Acclinate?
Acclinate operates at the intersection of digital health and clinical research, specifically targeting the lack of representation in genomic studies and pharmaceutical trials. Founded by Del Smith and Tiffany Jordan-Whitlow, the company provides a trusted platform that educates and engages diverse communities, empowering individuals to make informed health decisions. By facilitating better access to clinical trials, Acclinate enables biopharmaceutical companies and contract research organizations to gather more comprehensive, representative data, which is essential for the development of effective, universal medical treatments.
How much funding has Acclinate raised?
Acclinate has raised a total of $10.5M across 2 funding rounds:
Series A
$7M
Debt
$3.5M
Series A (2024): $7M with participation from Labcorp
Debt (2026): $3.5M, investors not publicly disclosed
Key Investors in Acclinate
Labcorp
Labcorp is a global leader in laboratory services, providing essential diagnostic and biopharma laboratory solutions to healthcare providers, researchers, and pharmaceutical companies worldwide.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Acclinate?
With this latest round of financing, Acclinate is well-positioned to scale its operations and deepen its impact within the biopharmaceutical sector. The company is expected to leverage this capital to enhance its digital engagement tools and expand its reach into new therapeutic areas where diversity in clinical data is paramount. As the industry shifts toward more personalized medicine, Acclinate's ability to provide high-quality, diverse participant cohorts will likely become a competitive advantage, potentially attracting further strategic partnerships and institutional backing to support its long-term mission of health equity.
See full Acclinate company page
